Recursion Pharmaceuticals Raises $436 million IPO
Recursion Pharmaceuticals raised $436M in IPO financing led by Various, with participation from Various (IPO). AI drug discovery using robotic biology and ML. The new capital is framed around Advance 7 clinical candidates and expand AI NVIDIA partnership.
What it does
AI drug discovery using robotic biology and ML. The business sits in Healthcare & Life Sciences, where funded companies are using fresh capital to deepen product coverage, distribution, or operating capacity.
Traction
Running 2M+ experiments/week; AI maps cellular biology for drug target identification. Management framed the new capital around Advance 7 clinical candidates and expand AI NVIDIA partnership.
Trend impact
Automated AI drug discovery competing with Insilico and Exscientia. The capital raise matters because it gives the company more room to compete for customers, talent, and mindshare while incumbents and adjacent startups respond with clearer product depth or distribution.
Funding history
- April 1, 2021 · IPO · $436 million · Various (IPO)
- February 1, 2025 · Growth Round · $150 million · NVIDIA
- June 1, 2023 · Growth Round · $150 million · NVIDIA
Products & services
- Healthcare & Life Sciences workflow monitoring tied to the funding announcement
- Customer-facing product described on the company website
- Operational tooling for healthcare & life sciences teams
- Data capture and reporting across core business processes
- Team expansion support funded by the latest round